Lumida
/BCRX
⌘K
BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

BCRX
$8.12USD-2.05%-0.17 today

MARKET CAP

2.1B

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $8

52W RANGE

$6
$11

AI Summary

Stalk
StalkMedium

Despite a decisive support failure on elevated volume, extreme oversold conditions have triggered mean-reversion eligibility, flipping the medium-term bias to bullish. However, short-term execution remains unfavorable as price trades below declining 9/20/50 EMAs and rejects on minor rebounds. We will stalk for a pullback into structural support around the 200-day SMA and prior consolidation lows under the Growth at Reasonable Price strategy before considering a long entry.

  • Q2 revenue rose 45% YoY to $213.9M, driven by ORLADEYO demand.
  • Consensus price target of $20.60 implies 108% upside potential.
  • Negative earnings yield and low book-to-price point to premium valuation.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$157.2M$270.8M$331.4M$450.7M$874.8M
YoY %+782.4%+72.3%+22.4%+36.0%+94.1%
P / Sales15.8x7.9x3.5x3.4x1.9x
EV / Sales17.0x9.9x6.1x5.4x2.6x
Gross Profit, Adj.$149.9M$264.4M$326.9M$438.4M$855.8M
YoY %+822.0%+76.3%+23.6%+34.1%+95.2%
Margin %95.4%97.6%98.6%97.3%97.8%
EV / Gross Profit17.8x10.1x6.2x5.5x2.6x
EBITDA, Adj.$-176.9M$-147.0M$-102.1M$-1.3M$342.4M
YoY %-1.7%+16.9%+30.6%+98.7%+26497.7%
Margin %-112.6%-54.3%-30.8%-0.3%39.1%
EV / EBITDA-15.1x-18.2x-19.9x-1862.8x6.6x
EBIT$-177.7M$-148.4M$-103.7M$-2.5M$341.0M
YoY %-1.7%+16.5%+30.1%+97.5%+13508.9%
Margin %-113.1%-54.8%-31.3%-0.6%39.0%
EV / EBIT-15.0x-18.0x-19.6x-950.1x6.6x
Net Income$-184.1M$-247.1M$-226.5M$-88.9M$263.9M
YoY %-0.7%-34.3%+8.3%+60.8%+396.9%
Net Margin-117.1%-91.2%-68.4%-19.7%30.2%
EPS (GAAP)-$1.03-$1.33-$1.18-$0.43$1.21
YoY %+5.5%-29.1%+11.3%+63.6%+381.4%